Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial

Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial

Abstract Background Pancreatic cancer is the fourth leading cause of cancer-related death. While surgical resection remains the foundation for potentially curative treatment, survival benefit is achieved with adjuvant oncological treatment. Thus, completion of multimodality treatment (surgical resec...

Full description

Bibliographic Details
Main Authors: Knut Jørgen Labori, Kristoffer Lassen, Dag Hoem, Jon Erik Grønbech, Jon Arne Søreide, Kim Mortensen, Rune Smaaland, Halfdan Sorbye, Caroline Verbeke, Svein Dueland
Format: Article
Language:English
Published: BMC 2017-08-01
Series:BMC Surgery
Subjects:
Resectable pancreatic cancer
Neoadjuvant chemotherapy
Overall survival
Online Access:http://link.springer.com/article/10.1186/s12893-017-0291-1

Internet

http://link.springer.com/article/10.1186/s12893-017-0291-1

Similar Items